Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662413613P | 2016-10-27 | 2016-10-27 | |
US201662413586P | 2016-10-27 | 2016-10-27 | |
PCT/US2017/058451WO2018081367A1 (en) | 2016-10-27 | 2017-10-26 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors |
Publication Number | Publication Date |
---|---|
SG11201902886SAtrue SG11201902886SA (en) | 2019-05-30 |
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202107777XASG10202107777XA (en) | 2016-10-27 | 2017-10-26 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors |
SG11201902873RASG11201902873RA (en) | 2016-10-27 | 2017-10-26 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors |
SG11201902886SASG11201902886SA (en) | 2016-10-27 | 2017-10-26 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors |
SG11201902879SASG11201902879SA (en) | 2016-10-27 | 2017-10-26 | Immunoglobulins and uses thereof |
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202107777XASG10202107777XA (en) | 2016-10-27 | 2017-10-26 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors |
SG11201902873RASG11201902873RA (en) | 2016-10-27 | 2017-10-26 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors |
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201902879SASG11201902879SA (en) | 2016-10-27 | 2017-10-26 | Immunoglobulins and uses thereof |
Country | Link |
---|---|
US (15) | US10961293B2 (en) |
EP (5) | EP3532486B8 (en) |
JP (6) | JP7231539B2 (en) |
KR (6) | KR102653376B1 (en) |
CN (4) | CN110099692B (en) |
AU (6) | AU2017348180B2 (en) |
BR (3) | BR112019008500A2 (en) |
CA (3) | CA3041674A1 (en) |
CL (3) | CL2019001110A1 (en) |
CO (3) | CO2019003938A2 (en) |
CR (3) | CR20190208A (en) |
CY (1) | CY1124732T1 (en) |
DK (1) | DK3532486T3 (en) |
DO (3) | DOP2019000106A (en) |
EC (3) | ECSP19029995A (en) |
ES (2) | ES3025907T3 (en) |
HR (1) | HRP20211626T1 (en) |
HU (1) | HUE056442T2 (en) |
IL (6) | IL266204B2 (en) |
JO (3) | JOP20190097A1 (en) |
LT (1) | LT3532486T (en) |
MA (3) | MA46665B1 (en) |
MD (1) | MD3532486T2 (en) |
MX (6) | MX2019004954A (en) |
MY (1) | MY199666A (en) |
NI (2) | NI201900043A (en) |
PE (3) | PE20190917A1 (en) |
PH (3) | PH12019500723A1 (en) |
PL (1) | PL3532486T3 (en) |
PT (1) | PT3532486T (en) |
RS (1) | RS62677B1 (en) |
SA (3) | SA519401647B1 (en) |
SG (4) | SG10202107777XA (en) |
SI (1) | SI3532486T1 (en) |
SM (1) | SMT202100647T1 (en) |
TW (4) | TWI794189B (en) |
UY (3) | UY37457A (en) |
WO (3) | WO2018081370A1 (en) |
ZA (1) | ZA202200648B (en) |
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3546474B1 (en) | 2013-12-18 | 2021-07-07 | President and Fellows of Harvard College | Crp capture/detection of gram positive bacteria |
JOP20190097A1 (en)* | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | Immunoglobulins and uses thereof |
TWI847981B (en)* | 2018-04-25 | 2024-07-11 | 比利時商健生藥品公司 | Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof |
US11780900B2 (en) | 2018-04-25 | 2023-10-10 | Janssen Sciences Ireland Unlimited Company | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof |
WO2020188510A2 (en)* | 2019-03-19 | 2020-09-24 | Enzene Biosciences Limited | Process of preparation of glucagon-like peptide-1 (glp-1) receptor agonists and their analogs |
WO2020262590A1 (en)* | 2019-06-28 | 2020-12-30 | 味の素株式会社 | Cyclic peptide production method |
AU2020384729A1 (en) | 2019-11-11 | 2022-04-14 | Boehringer Ingelheim International Gmbh | NPY2 receptor agonists |
CN111494606B (en)* | 2020-04-24 | 2021-12-14 | 广州医科大学 | New application of neuropeptide Y |
CN116171282A (en) | 2020-08-07 | 2023-05-26 | 勃林格殷格翰国际有限公司 | Soluble NPY2 receptor agonist |
CN115073556A (en)* | 2021-03-12 | 2022-09-20 | 上海天慈生命科学发展有限公司 | Opioid/neuropeptide FF receptor multi-target cyclic peptide molecule and preparation and application thereof |
CN118076367A (en)* | 2021-06-14 | 2024-05-24 | 达比克斯有限责任公司 | GLP-1 receptor agonists with improved pharmacological and drug delivery properties |
WO2023097363A1 (en)* | 2021-11-30 | 2023-06-08 | Garvan Institute Of Medical Research | Improved binding proteins and uses thereof |
CN115028551B (en)* | 2022-07-15 | 2024-01-05 | 成都普康生物科技有限公司 | Preparation method of azide-nine glycol-propionic acid |
CN116098987A (en)* | 2023-02-09 | 2023-05-12 | 华东医院 | Use of galanin in the preparation of medicines for treating non-alcoholic fatty liver disease |
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2434149A1 (en) | 1978-06-22 | 1980-03-21 | Parcor | NEW L-CYSTEIN DERIVATIVES |
US5393669A (en)* | 1993-02-05 | 1995-02-28 | Martek Biosciences Corp. | Compositions and methods for protein structural determinations |
US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
WO2005077094A2 (en) | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Inc. | Pancreatic polypeptide family motifs and polypeptides comprising the same |
EP1718671A2 (en) | 2004-02-23 | 2006-11-08 | Rheoscience A/S | Peptide yy analogues |
WO2005089789A2 (en)* | 2004-03-17 | 2005-09-29 | 7Tm Pharma A/S | Y2 selective receptor agonists for therapeutic interventions |
MX2007002856A (en) | 2004-09-02 | 2007-09-25 | Genentech Inc | Heteromultimeric molecules. |
TWI544076B (en) | 2005-03-31 | 2016-08-01 | Chugai Pharmaceutical Co Ltd | A method of manufacturing a polypeptide that controls assembly |
DE102005028778A1 (en) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Multi-layer foil, useful for lining a flexible container, comprises a barrier layer, a stretch-poor plastic layer, an antistatic plastic layer and a layer containing a safe material for food |
WO2007100535A2 (en) | 2006-02-22 | 2007-09-07 | Merck & Co., Inc. | Oxyntomodulin derivatives |
US20090186817A1 (en)* | 2006-03-21 | 2009-07-23 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
KR20090074787A (en) | 2006-10-05 | 2009-07-07 | 센토코 오르토 바이오테크 인코포레이티드 | CrC2 antagonist for the treatment of fibrosis |
JP2008169195A (en)* | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | Insulin secretory peptide drug conjugates using carrier substances |
EP2527369A3 (en)* | 2007-09-13 | 2012-12-19 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
JP2011507519A (en) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | Design and generation of human de novo pIX phage display library via fusion to pIX or pVII, vectors, antibodies, and methods |
EP2362881B1 (en) | 2008-11-04 | 2019-03-13 | Janssen Pharmaceutica NV | Crhr2 peptide agonists and uses thereof |
MX2011004427A (en)* | 2008-11-05 | 2011-05-31 | Hoffmann La Roche | Neuropeptide-2-receptor (y-2r) agonists and uses thereof. |
JP2012525149A (en) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Method for making heteromultimeric molecules |
CN102574903B (en) | 2009-07-13 | 2015-07-08 | 西兰制药公司 | Acylated glucagon analogues |
WO2011033068A1 (en) | 2009-09-18 | 2011-03-24 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
KR20120092611A (en) | 2009-09-30 | 2012-08-21 | 글락소 그룹 리미티드 | Drug fusions and conjugates with extended half life |
SMT202400377T1 (en) | 2010-04-20 | 2025-01-14 | Genmab As | FC-CONTAINING PROTEINS OF HETERODIMERIC ANTIBODIES AND METHODS FOR THEIR PRODUCTION |
CA2812389C (en)* | 2010-09-27 | 2019-12-31 | John Kehoe | Antibodies binding human collagen ii |
US8906649B2 (en) | 2010-09-27 | 2014-12-09 | Janssen Biotech, Inc. | Antibodies binding human collagen II |
DK2635607T3 (en) | 2010-11-05 | 2019-11-18 | Zymeworks Inc | STABLE HETERODIMED ANTIBODY DESIGN WITH MUTATIONS IN THE FC DOMAIN |
KR20190090055A (en)* | 2011-01-28 | 2019-07-31 | 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 | Human antibodies to pcsk9 for use in methods of treating particular groups of subjects |
AR086969A1 (en) | 2011-06-17 | 2014-02-05 | Hanmi Science Co Ltd | CONJUGATE UNDERSTANDING OXONTOMODULIN AND A FRAGMENT OF IMMUNOGLOBULIN, AND ITS USE |
RU2675319C2 (en) | 2011-11-04 | 2018-12-18 | Займворкс Инк. | STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN Fc DOMAIN |
SI2869848T1 (en) | 2012-07-04 | 2017-01-31 | F. Hoffmann-La Roche Ag | Covalently linked antigen-antibody conjugates |
SG11201503370WA (en) | 2012-11-06 | 2015-05-28 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
SG11201504920SA (en) | 2012-12-27 | 2015-07-30 | Sanofi Sa | Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof |
CN105073781A (en) | 2013-01-11 | 2015-11-18 | 加州生物医学研究所 | bovine fusion antibody |
SG11201508469YA (en) | 2013-05-02 | 2015-11-27 | Glaxosmithkline Ip Dev Ltd | Therapeutic peptides |
DK3129406T3 (en)* | 2014-04-11 | 2019-04-01 | Medimmune Llc | CONJUGATED COMPOUNDS INCLUDING CYSTEIN MODIFIED ANTIBODIES |
AR100978A1 (en) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME |
MD20170020A2 (en) | 2014-07-30 | 2017-07-31 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
JP2018534933A (en)* | 2015-11-02 | 2018-11-29 | ヤンセン ファーマシューティカ エヌ.ベー. | Anti-IL1RAP antibody, bispecific antigen-binding molecule that binds IL1RAP and CD3, and use thereof |
JOP20190097A1 (en)* | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | Immunoglobulins and uses thereof |
TWI847981B (en)* | 2018-04-25 | 2024-07-11 | 比利時商健生藥品公司 | Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof |
Publication | Publication Date | Title |
---|---|---|
SG11201902886SA (en) | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201908650PA (en) | Optimized antibody compositions for treatment of ocular disorders | |
SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
SG11201900482SA (en) | Compounds and compositions as inhibitors of endosomal toll-like receptors | |
SG11201906417RA (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201906427QA (en) | Heterocyclic spiro compounds as magl inhibitors | |
SG11201803726VA (en) | Method for applying stable coating on silicone hydrogel contact lenses | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201906163TA (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
SG11201408173WA (en) | Pyrimidinyl tyrosine kinase inhibitors | |
SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
SG11201803757UA (en) | N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases | |
SG11201811712QA (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201908097YA (en) | Pyrimidine derivatives as pge2 receptor modulators | |
SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201901249YA (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
SG11201908729UA (en) | Phenyl derivatives as pge2 receptor modulators | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof |